title: Circadian variation of serum leptin in healthy and diabetic men.
abstract: Leptin, from the Greek leptos, meaning thin (in reference to its ability to reduce body fat stores), is a hormone secreted primarily by adipocytes. At one time, leptin was portrayed as a potential means of combating obesity. Recently, leptin has been identified as a potent inhibitor of bone formation, acting through the central nervous system. Since numerous studies clearly show that bone remodeling is circadian rhythmic with peak activity during sleep, it is of interest to explore circadian variability in serum leptin. Accordingly, circadian characteristics of serum leptin were examined in 7 clinically healthy men and 4 obese men with type II diabetes. Blood samples were collected for 24 h at 3 h intervals beginning at 19:00. The dark (sleep) phase of the light-dark cycle extended from 22:30 to 06:30, with brief awakening for sampling at 01:00 and 04:00. Subjects consumed general hospital meals (2400 calories) at 16:30, 07:30, and 13:30. Serum leptin levels were determined by a R&D Systems enzyme immunoassay technique. Data were analyzed by linear least-squares estimation using the population multiple components method. A statistically significant (P < .018) circadian rhythm modeled by a single 24 h cosine curve characterized the data of each group. The 24 h mean leptin level was statistically greater (P < .001) in the obese diabetic men than in the healthy men (9.47 +/- 0.66 ng/mL vs. 24.07 +/- 1.71 ng/mL, respectively). Higher leptin levels occurred between midnight and roughly 02:30, and lowest leptin levels occurred between noon and the early afternoon. The phasing of this rhythm is similar to the circadian rhythm in bone remodeling previously described. Our results suggest the findings from a single morning blood sampling for leptin may be misleading since it may underestimate the mean 24 h and peak concentrations of the hormone.
authors.affiliation: Department of Veterans Affairs, Edward Hines Jr. Hospital, Hines, Illinois 60141, USA. kanabrocki@aol.com
authors.forename: E L
authors.initials: EL
authors.lastname: Kanabrocki
authors.forename: R C
authors.initials: RC
authors.lastname: Hermida
authors.forename: M
authors.initials: M
authors.lastname: Wright
authors.forename: R M
authors.initials: RM
authors.lastname: Young
authors.forename: F W
authors.initials: FW
authors.lastname: Bremner
authors.forename: J L
authors.initials: JL
authors.lastname: Third
authors.forename: M D
authors.initials: MD
authors.lastname: Ryan
authors.forename: D E
authors.initials: DE
authors.lastname: Ayala
authors.forename: M
authors.initials: M
authors.lastname: Johnson
authors.forename: B A
authors.initials: BA
authors.lastname: Nemchausky
authors.forename: P
authors.initials: P
authors.lastname: Shirazi
authors.forename: L E
authors.initials: LE
authors.lastname: Scheving
authors.forename: J H
authors.initials: JH
authors.lastname: Olwin
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D016022:Case-Control Studies; D002940:Circadian Rhythm / Q000502:physiology*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D006801:Humans; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications
chemical_list: D001786:Blood Glucose; D007328:Insulin; D020738:Leptin